clinical trial · NCT03867097
Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)
Civi Biopharma, Inc.·phase2·completed·n = 34
Raynaud Phenomenon Secondary to Systemic SclerosisPlacebo IV infusionIloprost Injection, for intravenous use
brief summary
This is a Phase 2, multicenter, double-blind, randomized, placebo-controlled study to evaluate the effect of iloprost on the symptomatic relief of Raynaud's Phenomenon attacks in subjects with symptomatic Raynaud's Phenomenon secondary to Systemic Sclerosis.
started
Mar 7, 2019
primary completion
Aug 6, 2019
completion
Aug 6, 2019
last updated
May 25, 2025
official title
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol